BCTXZ BriaCell Therapeutics Corp. - Warrant
0.1553USD-22.35%Mkt Cap: —P/E: —6d ago
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-4.79M USD
Revenue/Share—
Last Price0.1553 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.08
EPS (TTM)—
EPS (Forward)—
52W Range
0.102036% of range0.2500
52W High0.2500 USD
52W Low0.1020 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE201.12%
ROA-81.59%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.13M USD
CapEx (TTM)456.80K USD
FCF Margin—
FCF Yield—
Net Debt-22.80M USD
Net Debt/EBITDA0.71
Balance Sheet
Debt/Equity—
Current Ratio7.07
Quick Ratio6.35
Book Value/Sh3.32 USD
Cash/Share2.62 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float7.86M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta1.51
S&P 52W Chg15.78%
Avg Vol (30d)25.73K
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—